Care teams are crucial for every aspect of healthcare. This course will review care team best practices which contain three important pillars: Collaboration, communication, and role definition as they relate to asthma and chronic obstructive pulmonary disease (COPD). With effective care teams, patient outcomes also improve, including decreased safety events, preventable diagnostic errors, and readmissions to hospitals. According to the Centers for Disease Control and Prevention (CDC), chronic lower respiratory conditions like COPD and asthma are the sixth leading cause of death (CDC, 2022b). Therefore, it is important to recognize the need for effective healthcare team approaches to improve patient outcomes for those with asthma and COPD.
New search functionality is now available for your account.
Feature Flag Details: Default value: false Flag: courseListSearch | User: 401099556
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Arkansas State Board Of Nursing Approved Continuing Education program (CEBroker Provider #50-290).

Bahamas Medical Council (CEBroker Provider #50-290)
Physicians will receive 0.50 AMA PRA category 1 Credits™.

District of Columbia Board of Nursing Approved Continuing Education program (CEBroker Provider #50-290).

Georgia Board of Nursing (CEBroker Provider #50-290)

Georgia Composite Medical Board - Physician Assistants (CEBroker Provider #50-290)

Kansas State Board of Nursing (CEBroker Provider #50-290)

Kentucky Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 0.50 contact hours for participating in this course.

Louisiana State Board of Medical Examiners (CEBroker Provider #: 50-290)

Physicians will receive 0.50 AMA PRA category 1 Credits™.

Michigan Board of Nursing (CEBroker Provider #50-290)

Mississippi Board of Nursing (CEBroker Provider #50-290)

Mississippi State Board of Medical Licensure (CEBroker Provider #: 50-290)

New Hampshire Medical Society (CEBroker Provider #50-290)
Physicians will receive 0.50 AMA PRA category 1 Credits™.

New Mexico Board of Nursing (CEBroker Provider #50-290)

Physicians will receive 0.50 AMA PRA category 1 Credits™.

North Dakota Board of Nursing (CEBroker Provider #50-290)

State Medical Board of Ohio (CEBroker Provider #: 50-290)

South Carolina Board of Medical Examiners (CEBroker Provider #50-290)

South Carolina Board of Nursing (CEBroker Provider #50-290)

Tennessee Board of Medical Examiners (CEBroker Provider #50-290)>
Physicians will receive 0.50 AMA PRA category 1 Credits™

Wyoming Board of Nursing (CEBroker Provider #50-290)
Outline:
Section 1: Introduction
About This Course
Learning Objectives
Section 2: Care Team Best Practices Overview
Collaboration
Team-Oriented and Patient Communication
Defining Roles
Review
Section 3: Asthma Care Team Approach
Meet Julian
Disease Overview
Signs and Symptoms
Diagnosis
Treatment
Care Team Best Practices
Review
Section 4: COPD Care Team Approach
Meet Olivia
Disease Overview
Signs and Symptoms
Diagnosis
Treatment
Care Team Best Practices
Review
Section 5: Conclusion
Course Summary
Course Contributor
References
Shalla is a subject matter expert (SME)/writer for Relias. She completed her BSN and two undergraduate degrees with top honors from the University of Wisconsin-Madison. Shalla earned her dual MSN degrees from Johns Hopkins University with top honors. She also maintains her post-baccalaureate nurse educator certificate (NE-BC). Shalla’s tenure spans over 20 years of cross-functional leadership and direct clinical roles in healthcare, biopharma/biotech, government affairs, managed care/market access, nonprofit patient advocacy, and research. Her subject matter expertise is in rare, orphan, and complex diseases. Her sub-expertise is in immune-mediated diseases (rheumatology and immunology), genetics, neurology, hematology/oncology, several pediatric diseases, population/public health, and larger systemic healthcare affairs. Shalla is a published author with leading rare disease experts and a global speaker. She also sits on scientific, advocacy, and legislative advisory boards. She has led national advocacy and disease awareness campaigns, including speaking before congress, leading to the first-in-class rare disease biologic approval and investigative treatment protocols.
Access to over 1,450 courses! Access to 1,450+ courses for one low price.